| Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells P Metzger, SV Kirchleitner, M Kluge, LM König, S Endres, CC Friedel, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810042, 2018 | 1 | 2018 |
| Investigating a potential role of Got1 in T cell exhaustion. N Weisshaar Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810040, 2018 | 1 | 2018 |
| Progression of head and neck cancer is associated with elevated neutrophil extracellular traps formation by circulating neutrophils AS Decker, E Pylaeva, A Brenzel, S Bordbari, I Spyra, S Lang, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810059, 2018 | 1 | 2018 |
| Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas L Meder, P Schuldt, M Thelen, A Schmitt, F Dietlein, S Klein, S Borchmann, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810057, 2018 | | 2018 |
| Specific targeting of oncogenic mutations using CRISPR-technology to destroy activated oncogenes and enhance immune response F Oppel, M Schürmann, H Sudhoff Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810046, 2018 | | 2018 |
| Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma C Rong, B Feng, M Muller, D Holzinger, C Flechtenmacher, J Thierauf, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810047, 2018 | | 2018 |
| Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo E Freund, R Clemen, RK Gandhirajan, S Bekeschus Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810055, 2018 | | 2018 |
| CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer H Sudhoff, L Masterson, P Jani, JC Sterling, P Goon Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810050, 2018 | | 2018 |
| Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies? Y Bartsch, M Ehlers Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810053, 2018 | | 2018 |
| Pre-and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma J Schröder, S Rödiger, M Ruhe, PM Deckert Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810056, 2018 | | 2018 |
| Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies V Bauer, F Ahmetlic, T Riedel, N Trautwein, T Sparwasser, S Stevanovic, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810045, 2018 | | 2018 |
| Current status of radiotherapy/radiochemotherapy and immunotherapy combinations–a German survey L Käsmann, C Eze, O Roengvoraphoj, C Belka, F Manapov Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810051, 2018 | | 2018 |
| Activation of immune response in refractory patients to standard treatment (TRANSLATE) A Abbona, D Sangiolo, M Merlano, O Garrone, M Anna, M Monteverde, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810052, 2018 | | 2018 |
| Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7 E Kabore, F Köster, S Polack, A Rody, K Bräutigam Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810044, 2018 | | 2018 |
| The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis F Ender, M Klee, M Kramer, A Merseburger, R Pries, G Riemekasten, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810048, 2018 | | 2018 |
| Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines P Vogt, F Köster, S Polack, A Rody, K Bräutigam Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810043, 2018 | | 2018 |
| Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells K Schütze, J Hambach, K Petry, W Fumey, B Albrecht, L Schriewer, ... Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810041, 2018 | | 2018 |
| Neo-adjuvant checkpoint inhibition–the pathway towards personalized immunotherapy C Blank Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810023, 2018 | | 2018 |
| Modulating the tumor microenvironment D Jäger Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810027, 2018 | | 2018 |
| Role of glycolysis for intestinal inflammation and carcinogenesis J Hamm, K Klischies, N Sommer, P Rosenstiel, F Sommer Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810037, 2018 | | 2018 |
